Friday 6 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue: +23.2%
EPS: −264.7%
Free cash flow: −7.23%
Total debt: 0.00%

Quarter to June 2026, against a year earlier

118.35 2.26 −1.87%

Follow TWST

Alert me

Market cap: $7.9B
P/E: 0.0×
Fwd P/E: −91.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.44
Beneish M: −2.30
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Twist Bioscience Corporation (TWST) Debt to equity

Alert me on Debt to equity

Twist Bioscience Corporation's debt to equity at the end of the quarter to 30 June 2026 was 0.0×, up 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2024) to 0.1× (fiscal 2017); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TWST/debt-to-equity" width="100%" height="360" style="border:0" loading="lazy" title="Twist Bioscience Corporation debt to equity, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TWST/metrics/debt-to-equity">Twist Bioscience Corporation (TWST) debt to equity — stockrow.com</a></p>

Period	Debt to equity	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.1×	23.30%
FY2022	0.1×	9.34%
FY2021	0.1×	568.09%
FY2020	0.0×	(72.24%)
FY2019	0.1×	(53.44%)
FY2018	0.1×	(21.00%)
FY2017	0.1×	—
FY2016	0.0×	—

Period	Debt to equity	Change
Jun 2026	0.0×	2.12%
Mar 2026	0.0×	0.30%
Dec 2025	0.0×	3.79%
Sep 2025	0.0×	0.96%
33 more quarters	Free account

Against its own ten years

Low 0.0× High 0.1×

Ten-year median 0.1×

Current reading's percentile 40

Company	Debt to equity
IBRX ImmunityBio, Inc. compare	−0.7×
CYTK Cytokinetics, Incorporated compare	−0.5×
KRYS Krystal Biotech, Inc. compare	0.0×
CAI Caris Life Sciences,�Inc. compare	0.0×
SYRE Spyre Therapeutics, Inc. compare	0.0×
PTGX Protagonist Therapeutics, Inc. compare	0.0×
TWST Twist Bioscience Corporation	0.0×
MDGL Madrigal Pharmaceuticals, Inc. compare	0.5×
TGTX TG Therapeutics, Inc. compare	1.2×
Biotechnology industry median	0.0×
Healthcare sector median	0.0×
Market median	0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

Twist Bioscience Corporation (TWST) Debt to equity

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on TWST

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on TWST

Stockrow Weekly